Needham downgrades Biogen on slow growth of Alzheimer's drug
Investing.com - Needham downgraded Biogen Inc (NASDAQ: BIIB) on Monday, citing slower-than-expected growth for its ...
GlobalData on MSN21h
How decentralisation can fill the gaps in Alzheimer’s research
Alzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital ...
Biogen cut to hold by Needham on lack of catalysts, slow Leqembi sales
Needham has downgraded Biogen (BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the company’s ...
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug ...
Worldcrunch on MSN16h
Leqembi, Is This New Drug The Turning Point In Curing Alzheimer’s?
That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...
Fintel on MSN17h
Needham Downgrades Biogen (BIIB)
Fintel reports that on November 18, 2024, Needham downgraded their outlook for Biogen (NasdaqGS:BIIB) from Buy to Hold.
CounterPunch8h
RFK Jr is a Whacked-Out Crank, But He’s Right About Big Pharma
And this corruption even extends into the Food and Drug Administration (FDA). Three years ago, Biogen got the FDA to approve its Alzheimer drug Aduhelm, even though there was little proof of its ...
Biogen downgraded to Hold from Buy at Needham
Needham analyst Ami Fadia downgraded Biogen (BIIB) to Hold from Buy.Don't Miss our Black Friday Offers:Discover the latest stocks recommended ...
Global News11h
GlobalNews homepage
Canadians will get child benefit cheques this week amid Canada Post strike Canadians will get child benefit cheques this week amid Canada Post strike Parents who are expecting child benefit ...